| 1 | SERPINF1, SOST
|
| Pigment epithelium derived factor suppresses expression of Sost/Sclerostin by osteocytes: implication for its role in bone matrix mineralization.
|
| Li F, Song N, Tombran-Tink J, Niyibizi C.
|
| J Cell Physiol 230(6):1243-9. doi: 10.1002/jcp.24859.
2015
|
| 2 | SOST
|
| Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus.
|
| Catalano A, Pintaudi B, Morabito N, Di Vieste G, Giunta L, Bruno ML, Cucinotta D, Lasco A, Di Benedetto A.
|
| Eur J Endocrinol 171(3):293-300. doi: 10.1530/EJE-14-0106. Epub 2014 Jun 2.
2014
|
| 3 | SOST, VDR
|
| Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.
|
| Menon VB, Moysés RM, Gomes SA, de Carvalho AB, Jorgetti V, Heilberg IP.
|
| Clin J Am Soc Nephrol 9(7):1263-70. doi: 10.2215/CJN.10030913. Epub 2014 Apr 24.
2014
|
| 4 | SOST
|
| Sclerostin deficiency is linked to altered bone composition.
|
| Hassler N, Roschger A, Gamsjaeger S, Kramer I, Lueger S, van Lierop A, Roschger P, Klaushofer K, Paschalis EP, Kneissel M, Papapoulos S.
|
| J Bone Miner Res 29(10):2144-51. doi: 10.1002/jbmr.2259.
2014
|
| 5 | SOST
|
| Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta.
|
| Kocijan R, Muschitz C, Fahrleitner-Pammer A, Amrein K, Pietschmann P, Haschka J, Dinu S, Kapiotis S, Resch H.
|
| J Clin Endocrinol Metab 99(2):E311-9. doi: 10.1210/jc.2013-2244. Epub 2013 Nov 7.
2014
|
| 6 | SOST
|
| Effect of liver dysfunction on circulating sclerostin.
|
| Rhee Y, Kim WJ, Han KJ, Lim SK, Kim SH.
|
| J Bone Miner Metab 32(5):545-9. doi: 10.1007/s00774-013-0524-z. Epub 2013 Oct 15.
2014
|
| 7 | GLI3, SOST, SOSTDC1
|
| Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner.
|
| Collette NM, Yee CS, Murugesh D, Sebastian A, Taher L, Gale NW, Economides AN, Harland RM, Loots GG.
|
| Dev Biol ev Biol. 2013 Aug 29. doi:pii: S0012-1606(13)00440-5. 10.1016/j.ydbio.2013.08.015. [Epub ahead of print]
2013
|
| 8 | BMP2, DKK1, SOST
|
| High-concentration of BMP2 reduces cell proliferation and increases apoptosis via DKK1 and SOST in human primary periosteal cells.
|
| Kim HK, Oxendine I, Kamiya N.
|
| Bone 54(1):141-50. doi: 10.1016/j.bone.2013.01.031. Epub 2013 Jan 27.
2013
|
| 9 | SOST
|
| Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
|
| Kogawa M, Wijenayaka AR, Ormsby RT, Thomas GP, Anderson PH, Bonewald LF, Findlay DM, Atkins GJ.
|
| J Bone Miner Res 28(12):2436-48. doi: 10.1002/jbmr.2003.
2013
|
| 10 | BMP6, NOG, SOST
|
| Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression.
|
| Yuen HF, McCrudden CM, Grills C, Zhang SD, Huang YH, Chan KK, Chan YP, Wong ML, Law S, Srivastava G, Fennell DA, Dickson G, El-Tanani M, Chan KW.
|
| Cancer Sci 103(6):1145-54. doi: 10.1111/j.1349-7006.2012.02252.x. Epub 2012 Apr 3.
2012
|
| 11 | DKK1, SOST
|
| Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.
|
| Ke HZ, Richards WG, Li X, Ominsky MS.
|
| Endocr Rev 33(5):747-83. doi: 10.1210/er.2011-1060. Epub 2012 Jun 20. Review.
2012
|
| 12 | SOST
|
| DNA methylation contributes to the regulation of sclerostin expression in human osteocytes.
|
| Delgado-Calle J, Sañudo C, Bolado A, Fernández AF, Arozamena J, Pascual-Carra MA, Rodriguez-Rey JC, Fraga MF, Bonewald L, Riancho JA.
|
| J Bone Miner Res 27(4):926-37. doi: 10.1002/jbmr.1491.
2012
|
| 13 | MEF2C, SOST
|
| Targeted deletion of Sost distal enhancer increases bone formation and bone mass.
|
| Collette NM, Genetos DC, Economides AN, Xie L, Shahnazari M, Yao W, Lane NE, Harland RM, Loots GG.
|
| Proc Natl Acad Sci U S A 109(35):14092-7. doi: 10.1073/pnas.1207188109. Epub 2012 Aug 10.
2012
|
| 14 | MEF2C, POSTN, PTH, SOST
|
| Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin.
|
| Bonnet N, Conway SJ, Ferrari SL.
|
| Proc Natl Acad Sci U S A 109(37):15048-53. doi: 10.1073/pnas.1203085109.
2012
|
| 15 | LRP4, SOST, SOST2
|
| Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function.
|
| Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, Bouwmeester T, Schirle M, Bueno-Lozano M, Fuentes FJ, Itin PH, Boudin E, de Freitas F, Jennes K, Brannetti B, Charara N, Ebersbach H, Geisse S, Lu CX, Bauer A, Van Hul W, Kneissel M.
|
| J Biol Chem 286(22):19489-500. Epub 2011 Apr 6.
2011
|
| 16 | CDD, SOST
|
| Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia.
|
| Kim SJ, Bieganski T, Sohn YB, Kozlowski K, Semënov M, Okamoto N, Kim CH, Ko AR, Ahn GH, Choi YL, Park SW, Ki CS, Kim OH, Nishimura G, Unger S, Superti-Furga A, Jin DK.
|
| Hum Genet 129(5):497-502. Epub 2011 Jan 9.
2011
|
| 17 | ACVR1, BMP7, DKK1, SOST
|
| Loss-of-function of ACVR1 in osteoblasts increases bone mass and activates canonical Wnt signaling through suppression of Wnt inhibitors SOST and DKK1.
|
| Kamiya N, Kaartinen VM, Mishina Y.
|
| Biochem Biophys Res Commun 414(2):326-30. doi: 10.1016/j.bbrc.2011.09.060. Epub 2011 Sep 17.
2011
|
| 18 | CYR61, SOST
|
| Sclerostin binds and regulates the activity of cysteine-rich protein 61.
|
| Craig TA, Bhattacharya R, Mukhopadhyay D, Kumar R.
|
| Biochem Biophys Res Commun 392(1):36-40. Epub 2009 Dec 31.PMID: 20043874 2010
|
| 19 | ESR1, ESR2, LRP4, LRP5, SOST, TNFRSF11A, TNFRSF11B, TNFSF11, VDR, WLS
|
| Genetics of osteoporosis: accelerating pace in gene identification and validation.
|
| Li WF, Hou SX, Yu B, Li MM, Férec C, Chen JM.
|
| Hum Genet 127(3):249-85. Epub 2009 Dec 12. Review.PMID: 20101412 2010
|
| 20 | SOST, SP7
|
| Sclerostin is a direct target of osteoblast-specific transcription factor osterix.
|
| Yang F, Tang W, So S, de Crombrugghe B, Zhang C.
|
| Biochem Biophys Res Commun 400(4):684-8. Epub 2010 Sep 8.
2010
|
| 21 | ERBB3, SOST
|
| Sclerostin-erbB-3 interactions: modulation of erbB-3 activity by sclerostin.
|
| Craig TA, Kumar R.
|
| Biochem Biophys Res Commun 402(2):421-4. Epub 2010 Oct 14.
2010
|
| 22 | SOST
|
| First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function.
|
| Piters E, Culha C, Moester M, Van Bezooijen R, Adriaensen D, Mueller T, Weidauer S, Jennes K, de Freitas F, Löwik C, Timmermans JP, Van Hul W, Papapoulos S.
|
| Hum Mutat 31(7):E1526-43.
2010
|
| 23 | SOST
|
| Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation.
|
| Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD.
|
| J Biol Chem 284(16):10890-900. Epub 2009 Feb 10.
2009
|
| 24 | SOST
|
| Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis.
|
| Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G.
|
| Arthritis Rheum 60(11):3257-62.PMID: 19877044 2009
|
| 25 | POSTN, SOST
|
| The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity.
|
| Bonnet N, Standley KN, Bianchi EN, Stadelmann V, Foti M, Conway SJ, Ferrari SL.
|
| J Biol Chem 284(51):35939-50. Epub .PMID: 19837663 2009
|
| 26 | BMP2, BMP4, BMP6, SOST, WNT10B
|
| Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate.
|
| Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ.
|
| Proc Natl Acad Sci U S A 105(52):20764-9. Epub 2008 Dec 15.
2008
|
| 27 | MEF2A, MEF2B, MEF2C, PTH, SOST
|
| Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
|
| Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H.
|
| J Bone Miner Res 22(12):1957-67.PMID: 17696759 2007
|
| 28 | LRP5, SOST
|
| LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.
|
| Semenov MV, He X.
|
| J Biol Chem 281(50):38276-84. Epub 2006 Oct 19.
2006
|
| 29 | LRP5, LRP6, SOST
|
| SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.
|
| Semenov M, Tamai K, He X.
|
| J Biol Chem 280(29):26770-5. Epub 2005 May 20. 2005
|
| 30 | PTH, SOST
|
| SOST is a target gene for PTH in bone.
|
| Keller H, Kneissel M.
|
| Bone 37(2):148-58. 2005
|
| 31 | SOST
|
| Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites.
|
| Uitterlinden AG, Arp PP, Paeper BW, Charmley P, Proll S, Rivadeneira F, Fang Y, van Meurs JB, Britschgi TB, Latham JA, Schatzman RC, Pols HA, Brunkow ME.
|
| Am J Hum Genet 75(6):1032-45. Epub 2004 Oct 26. 2004
|
| 32 | RUNX2, SOST
|
| Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST).
|
| Sevetson B, Taylor S, Pan Y.
|
| J Biol Chem 279(14):13849-58. Epub 2004 Jan 22. 2004
|
| 33 | SOST
|
| Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation.
|
| Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA.
|
| Bone 35(4):828-35. 2004
|
| 34 | SOST
|
| Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity.
|
| Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N.
|
| J Biol Chem 278(26):24113-7. Epub 2003 Apr 17. 2003
|
| 35 | HVB, MEOX1, SOST
|
| A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.
|
| Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME.
|
| Am J Med Genet 110(2):144-52. 2002
|
| 36 | BCC8, HVB, SOST
|
| Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.
|
| Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W.
|
| J Med Genet 39(2):91-7.PMID: 11836356 2002
|
| 37 | SOST
|
| Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.
|
| Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J.
|
| Am J Hum Genet 68(3):577-89. 2001
|
| 38 | SOST
|
| Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).
|
| Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W.
|
| Hum Mol Genet 10(5):537-43. 2001
|
| 39 | SOST
|
| Localization of the gene for sclerosteosis to the van buchem disease-gene region on chromosome 17q12-q21.
|
| Balemans W, et al.
|
| Am J Hum Genet 64(6):1661-9. 1999
|